Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC

Explore the current landscape of targeted therapies in non-small cell lung cancer, focusing on KRAS G12C mutations, molecular testing, and current treatments.

Experts review the current frontline treatments for patients with KRAS G12C-mutated NSCLC.

Shared insight into the consideration of KRAS G12C inhibitors in treating co-mutations in NSCLC.

Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.

A comprehensive review of hepatotoxicity in ongoing studies evaluating KRAS inhibitors in the frontline setting, highlighting adagrasib and sotorasib in the KRYSTAL-7 and CodeBreaK 100 studies, respectively.

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.

Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.

Shared insight on the clinical management of hepatotoxicity with use of KRAS G12C inhibitors in mNSCLC.

In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.